DAY101 Granted Rare Pediatric Disease Designation by the FDA for Pediatric Low-Grade Glioma
July 28, 2021

The phase 2 clinical trial is currently recruiting patients with pediatric low-grade glioma to be treated with DAY101 following a rare pediatric disease designation by the FDA.

Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
July 27, 2021

Oncologists are trying to remedy the proposed cuts to radiation oncology facilities from the Centers for Medicare and Medicaid Services to lessen health disparities and improve equitable access to care.

FDA Grants Clearance of Investigational New Drug Application for Lanraplenib in Combination With Gilteritinib for R/R FLT3+ AML
July 27, 2021

A phase 1/2 trial featuring lanraplenib/gilteritinib in patients with FLT3-mutant acute myeloid leukemia will proceed following the FDA’s clearance of an investigational new drug application.